New liquid viagra versions put to the test against popular ED pills

NCT ID NCT07117383

Not yet recruiting Symptom relief Sponsor: Aspargo Labs, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study will compare how two new liquid forms of sildenafil (Hezkue and Hezkue Turbo) are absorbed in the body versus several commercial ED products like Viagra and chewable tablets. Seventy-two healthy men will take single doses after a meal, and researchers will measure drug levels and side effects like headache or dizziness. The goal is to see if the new formulations offer any differences in absorption or tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sildenafil (the active ingredient in Viagra)
What this could lead to: If successful, this could show that Hezkue or Hezkue Turbo are absorbed differently than other sildenafil products, potentially offering a new option for erectile dysfunction.
What could go wrong: This is an early Phase 1 study in only 72 healthy men, not people with erectile dysfunction. It only measures absorption and short-term side effects, not whether the drugs actually work for ED.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERECTILE DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erectile dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERECTILE DYSFUNCTION

Contacts and locations

Locations

Aspargo Labs

New York, New York, 10004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.